Please assess the completion status of the following clinical trial:

Trial Title: BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV RNA ≥5000 c/ml~Exclusion Criteria:~* Any antiretroviral therapy within 30 days prior to screening;~* Women of Childbearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy for the entire study and for up to 8 weeks after the study;~* WOCBP using a prohibited contraceptive method~* WOCBP who are pregnant or breastfeeding;~* Women with a positive pregnancy test on enrollment or prior to study drug administration;~* Presence of a newly diagnosed HIV-Related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment;~* Suspected primary (acute) HIV infection;~* Prior antiviral therapy (\>30 days of NRTI and/or \>7 days of non-nucleoside reverse transcriptase inhibitor (NNRTI) or PI therapies) or any antiretroviral therapy within 30 days prior to screening; some exceptions are allowed for ARV therapy in use for Mother-to-child transmission;~* Participants with Cushing's syndrome;~* Untreated hypothyroidism or hyperthyroidism. A participant who is euthyroid on a stable replacement dose of thyroid hormone is acceptable provided the thyroid stimulating hormone (TSH) performed within 30 days of screening is within normal drug range;~* Recent therapy with agents with significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or expected need for such therapy at the time of enrollment; or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs that affect CYP3A4;~* Participants with obstructive liver disease;~* Active alcohol or substance use sufficient, in the Investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis;~* Proven or suspected acute hepatitis in the 30 days prior to study entry;~* Intractable diarrhea (≥6 loose stools/day for at least 7 consecutive days) within 30 days prior to study entry;~* Inability to swallow capsules;~* Active peripheral neuropathy;~* Presence of cardiomyopathy (due to any cause) or any significant cardiovascular disease, such as unstable ischemic heart disease;~* Known, clinically significant cardiac conduction system disease.~* Baseline laboratory values measured within 2 weeks prior to initiating study drugs as follows:~  1. calculated creatine clearance \<60 mL/min as estimated by the Cockcroft-Gault equation;~ 2. total serum lipase ≥ 1.4 times the upper limit of normal;~ 3. liver enzymes (AST, ALT) ≥ 5 times the upper limit of normal;~ 4. total serum bilirubin ≥ 1.5 times the upper limit of normal.~* Hypersensitivity to any component of the formulation of study drug;~* Prohibited therapies;~* Any other clinical conditions or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for study or unable to comply with the dosing requirements;~* Prisoners or participants who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atazanavir (ATV) + Ritonovir (RTV) (Type: ACTIVE_COMPARATOR): Participants were administered an oral dose of ATV 300 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of ATV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.
- Lopinavir (LPV) + RTV (Type: ACTIVE_COMPARATOR): Participants were administered an oral dose of LPV 400 mg and RTV 100 mg once daily along with food on a background of fixed dose combination TDF 300 mg plus FTC 200 mg (TDF/FTC) once daily. Doses of LPV and RTV were taken 24 hours apart at the same time as the background TDF/FTC, up to 96 Weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).